News
- Information Day on Multiple Myeloma in Barcelona 2023 | Dr. Carlos Fernández de Larrea
3rd Video of our Barcelona 2023 Conference with Dr. Carlos Fernández de Larrea, Director of the UB Amgen Chair of … - Information Conference on Multiple Myeloma 2023 | Cemmp
Multiple Myeloma Conferences 2023: In this section of our page you can see the information sessions on Multiple Myeloma that … - The UB joins forces with AMGEN to improve training in multiple myeloma
The University of Barcelona has, since yesterday, a new chair: the UB AMGEN Chair in Multiple Myeloma. Thanks to the …
Publications
- Bilateral orbital plasmacytomas as first sign of extramedullary progression post CAR-T therapy: case report and literature review
- Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia
- Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
- Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
- Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström’s Macroglobulinemia on Management of Waldenström’s Macroglobulinemia Related Amyloidosis
Research Projects
- Novel Advanced Engineering Strategies to Optimize CAR-T Cell Function and Persistence in Multiple Myeloma
- Analysis of the chromatin accesibility landscape and regulatory networks of igm monoclonal gammopathies: Towards a better understanding of progression mechanisms
- Immunotherapy for Multiple Myeloma
- Results-Oriented Cooperative Research Networks in Greeting 2021
- Strategies to overcome antigen escape relapses and improve CAR T-cell persistence in multiple myeloma
- Optimization of immunotherapy with CAR T cells through the inhibition of immune checkpoints to achieve a prolonged response in patients with multiple myeloma